Genetic spectrum and clinical profiles in a southeast Chinese cohort of Charcot‐Marie‐Tooth disease

• Published in: Clinical genetics 2019-11, Vol.96 (5), p.439-448
• Main Authors: Chen, Cong‐Xin, Dong, Hai‐Lin, Wei, Qiao, Li, Li‐Xi, Yu, Hao, Li, Jia‐Qi, Liu, Gong‐Lu, Li, Hong‐Fu, Bai, Ge, Ma, Huan, Wu, Zhi‐Ying
• Format: Article
• Language: English
• Subjects: Charcot‐Marie‐tooth disease; clinical profile; Diagnosis; Genetic screening; genetic spectrum; Mutation; Neuropathy; Peripheral myelin protein 22; Sensorimotor system; targeted next‐generation sequencing
• ISSN: 0009-9163; 1399-0004
• DOI: 10.1111/cge.13616

Charcot‐Marie‐Tooth (CMT) disease is a heterogeneous group of inherited sensorimotor neuropathies. To clarify the genetic spectrum and clinical profiles in Chinese CMT patients, we enrolled 150 unrelated CMT patients from southeast China. We performed multiplex ligation‐dependent probe amplification (MLPA) testing in all patients and next‐generation sequencing (NGS) among those patients without PMP22 rearrangements. We identified PMP22 duplications in 40 patients and deletions in 12 patients. In addition, we found 19 novel variants and 36 known mutations in 57 patients. Among these 55 variants, 45 pathogenic or likely pathogenic variants were identified in 48 cases, and 10 variants with uncertain significance were identified in 9 cases. Therefore, we obtained a genetic diagnosis in 63.8% (88/138) of CMT patients and 66.7% (100/150) of all included patients. PMP22, GJB1, and MFN2 are the most common causative genes in CMT1 (demyelinated form), intermediate CMT, and CMT2 (axonal form), respectively. In this study, we identified a higher proportion of intermediate CMT, a relatively high frequency of NDRG1 mutations and clinical features of later onset age in CMT1A patients. Our results broaden the genetic and clinical spectrum of CMT patients, which can help optimize the genetic and clinical diagnosis.